The role of nitric oxide in the development of diabetic angiopathy

Hormone and Metabolic Research

Volumn 36, Issue 5, 2004, Pages 319-335

  Santilli, F ^a   Cipollone, F ^a   Mezzetti, A ^a   Chiarelli, F ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Diabetes; Endothelial dysfunction; Macroangiopathy; Nephropathy; Retinopathy

Indexed keywords

NITRIC OXIDE;

ANTICOAGULATION; APOPTOSIS; ARTICLE; BIOAVAILABILITY; CELL FUNCTION; CELL PROLIFERATION; CLINICAL FEATURE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HOMEOSTASIS; HUMAN; LEUKOCYTE ADHERENCE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; ULTRAFILTRATION; VASCULAR DISEASE; VASODILATATION;

ANIMALS; DIABETIC ANGIOPATHIES; DIABETIC RETINOPATHY; ENDOTHELIUM, VASCULAR; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MODELS, CARDIOVASCULAR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III;

GLOMERULUS;

EID: 2542533734     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-814489     Document Type: Article

References (194)

1. Head J, Fuller JH. International variations in mortality among diabetic patients: the WHO Multinational Study of Vascular disease in diabetics. Diabetologia 1990; 24: 336-341
2. Dorman JS, Laporte RE, Kuller LH, Cruickshanks KJ, Orchard TJ, Wagener DK, Becker DJ, Cavender DE, Drash AL. The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study. Mortality results. Diabetes 1984; 33: 271-276
3. Stehouwer CDA, Lambert J, Donker AJM, van Hinsbergh VWM. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997; 34: 55-68
4. Reddy KG, Nair R, Sheehan H, Hodgson J. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol 1994; 23: 833-843
5. Quyiumi AA, Dakak N, Andrews N, Hussain S, Arora S, Gilligan D, Panza JA. Nitric oxide activity in the human coronary circulation: impact of risk factors for coronary atherosclerosis. J Clin Invest 1995; 95: 1747-1753
6. Dzau VJ, Gibbons GH, Mann M, Braun-Dullaeus R. Future horizons in cardiovascular molecular therapies. Am J Cardiol 1997; 80 (9A): 33-39
7. Bell D, Johns TE, Lopez LM. Endothelial dysfunction: implications for therapy of cardiovascular diseases. Ann Pharmacother 1998; 32: 459-470
8. Ludmer PL, Selwyn AP, Shook LT, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315: 1046-1051
9. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-142
10. Leibovich SJ, Polverini PJ, Fong TW, Harlow LA, Koch AE. Production of angiogenic activity by human monocytes requires an L-arginine/nitric oxide-synthase-dependent effector mechanism. Proc Natl Acad Sci USA 1994; 91: 4190-4194
11. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991; 88: 4651-4655
12. Niu X, Smith CW, Kubes P. Intracellular oxidative stress induced by nitric oxide synthesis inhibition increases endothelial cell adhesion to neutrophils. Circ Res 1994; 74: 1133-1140
13. Dubey R, Jackson E, Luscher TF. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cells. J Clin Invest 1995; 96: 141-149
14. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774-1777
15. Von der Leyen H, Gibbons G, Morishita R, Lewis N, Zhang L, Nakajima M, Kaneda Y, Cooke J, Dzau VJ. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995; 92: 1137-1141
16. Cines DB, Pollak E, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA, Schmidt A-M, Stern DM. Endothelial cell in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-3561
17. Kanner J, Harel S, Granit R. Nitric oxide as an antioxidant. Arc Biochem Biophys 1991; 289: 130-136
18. Griffith TM, Edwards DH, Lewis MG, Newby AC, Henderson AH. The nature of endothelium-derived vascular relaxant factor. Nature 1984; 308: 645-647
19. Poston L, Taylor PD. Endothelium-mediated vascular function in insulin-dependent diabetes mellitus. Clin Sci 1995; 3: 245-255
20. Huvers FC, de Leeuw PW, Houben AJ, de Haan CH, Hamulyak K, Schouten H, Wolffenbuttel BH, Schaper NC. Endothelium-dependent vasodilatation, plasma markers of endothelial function, and adrenergic vasoconstrictor responses in type 1 diabetes under near-normoglycemic conditions. Diabetes 1999; 48: 1300-1307
21. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993; 88: 2510-2516
22. Lambert J, Aarsen M, Donker AJ, Stehouwer CD. Endothelium-dependent and -independent vasodilation of large arteries in normoalbuminuric insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996; 16: 705-711
23. Morris BJ, Markus A, Glenn CL, Adams DJ, Colagiuri D, Wang L. Association of a functional inducible nitric oxide synthase promoter variant with complications in type 2 diabetes. J Mol Med 2002; 80: 96-104
24. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 1994; 94: 1172-1179
25. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994; 94: 2511-2515
26. Grover A, Padginton C, Wilson MF, Sung BH, Izzo JL Jr, Dandona P. Insulin attenuates norepinephrine-induced venoconstriction. An Ultrasonographic Study. Hypertension 1995; 25: 779-784
27. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurements in vascular endothelial cells. J Clin Invest 1996; 98: 894-898
28. Aljada A, Dandona P. Effect of insulin on human aortic endothelial nitric oxide synthase. Metabolism 2000; 49: 147-150
29. Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 1990; 85: 1844-1852
30. Laakso M, Edelman SV, Brechtel G, Baron AD. Impaired insulin-mediated skeletal muscle bloodflow in patients with NIDDM. Diabetes 1992; 41: 1076-1083
31. Baron AD, Brechtel-Hook G, Johnson A, Hardin D. Skeletal muscle blood flow. A possible link between insulin resistance and blood pressure. Hypertension 1993; 21: 129-135
32. Baron AD, Brechtel G. Insulin differentially regulates systemic and skeletal muscle vascular resistance. Am J Physiol 1993; 265: E61-E67
33. Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, Quon M. Roles for insulin receptor, P13-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000; 101: 1539-1545
34. Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, Feener EP, Herbert TP, Rhodes CJ, King GL. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 2000; 101: 676-681
35. Weisbrod RM, Brown ML, Cohen RA. Effect of elevated glucose on cyclic GMP and eicosanoid produced by porcine aortic endothelium. Arterioscler Thromb 1993; 13: 915-923
36. Giugliano D, Marfella R, Coppola L, Verazzo G, Acampora R, Giunta R, Nappo F, Lucarelli C, D'Onofrio F. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine: evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 1997; 95: 1783-1790
37. Bucala R, Trace YKJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 1991; 87: 432-438
38. Kojda G, Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 1999; 43: 562-571
39. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-844
40. Thomson L, Trujillo M, Telleri R, Radi R. Kinetics of cytochrome c21 oxidation by peroxynitrite: implications for superoxide measurements in nitric oxide-producing biological systems. Arch Biochem Biophys 1995; 319: 491-497
41. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U, Munzel T. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 2001; 88: e14-e22
42. Shinozaki K, Kashiwagi A, Nishio Y, Okamura T, Yoshida Y, Masada M, Toda N, Kikkawa R. Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/O2-imbalance in insulin-resistant rat aorta. Diabetes 1999; 48: 2437-2445
43. Pieper GM. Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin.J Cardiovasc Pharmacol 1997; 29: 8-15
44. Meininger CJ, Marinos RS, Hatakeyama K, Martinez-Zaguilan R, Rojas JD, Kelly KA, Wu G. Impaired nitric oxide production in coronary endothelial cells of the spontaneously diabetic BB rat is due to tetrahydrobiopterin deficiency. Biochem J 2000; 349: 353-356
45. Munzel T, Li H, Mollnau H, Hink U, Matheis E, Hartmann M, Oelze M, Skatchkov M, Warnholtz A, Duncker L, Meinertz T, Forstermann U. Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability. Circ Res 2000; 86: e7-e12
46. Cosentino F, Hishikawa K, Katusic ZS, Luscher TF. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 1997; 96: 25-28
47. Mohanty P, Hamouda W, Garg R, Aljada A, Chanim H, Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leukocytes. J Clin Endocrinol Metab 2000; 85: 2970-2973
48. Mohanty P, Ghanim H, Hamouda W, Aljada A, Garg R, Dandona P. Both lipid and protein intake stimulate increased generation of reactive oxygen species by polymorphonuclear leukocytes and mononuclear cells. Am J Clin Nutr 2002; 75: 767-772
49. Milson AB, Jones CJ, Goodfellow J, Frenneaux MP, Peters JR, James PE. Abnormal metabolic fate of nitric oxide in type 1 diabetes mellitus. Diabetologia 2002; 45: 1515-1522
50. Ruggenenti P, Remuzzi G. Nephropathy of type-2-diabetes mellitus. J Am Soc Nephrol 1998; 9: 2157-2169
51. Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia 1999; 42: 263-285
52. Adler S. Structure-function relationships associated with extracellular matrix alterations in diabetic glomerulopathy. J Am Soc Nephrol 1994; 5: 1165-1172
53. Ziyadeh FN. Significance of tubulointerstitial changes in diabetic renal disease. Kidney Int 1996; 54: 10-13
54. Deckert T, Yokoyama H, Mathiesen E, Ronn B, Jensen T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen JS. Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patients with insulin dependent diabetes. BMJ 1996; 312: 871-874
55. Deckert T, Poulsen JE, Larsen M. Prognosis of diabetics with diabetes onset before the age of 31: survival, causes of death and complications. Diabetologia 1978; 14: 363-370
56. The DCCT Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. N Engl J Med 1993; 329: 977-986
57. Corbett JA, Triton RG, Chang K, Hassan KS, Ido Y, Wang JL, Sweetland MA, Lancaster JR, Williamson JR, McDaniel ML. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 1992; 41: 552-556
58. Graier WF, Wascher TC, Lackner L, Toplak H, Krejs GJ, Kukovetz WR. Exposure to elevated D-glucose concentrations modulates vascular endothelial cell vasodilatory response. Diabetes 1993; 42: 1497-1505
59. Pugliese G, Tilton RG, Williamson JR. Glucose-induced metabolic imbalances in the pathogenesis of diabetic vascular disease. Diabetes Metab Rev 1991; 7: 35-59
60. Tolins P, Shultz PJ, Raij L, Brown DM, Mauer SM. Abnormal renal hemodynamic response to reduced renal perfusion in diabetic rats: role of NO. Am J Physiol 1993; 265: F886-F895
61. Reyes AA, Karl IE, Kissane J, Klahr S. L-arginine administration prevents glomerular hyperfiltration and decreases proteinuria in diabetic rats. J Am Soc Nephrol 1993; 4: 1039-1045
62. Bank N, Aynedjian HS. Role of EDRF (nitric oxide) in diabetic renal hyper-filtration. Kidney Int 1993; 43: 1306-1312
63. Tolins JP, Palmer RMJ, Moncada S, Raij L. Role of endothelium-derived relaxing factor in regulation of renal hemodynamic responses. Am J Physiol 1990; 258: H655-H662
64. Nathan C, Xie QW. Regulation of biosynthesis of nitric oxide. J Biol Chem 1994; 269: 13725-13728
65. Kone BC, Baylis C. Biosynthesis and homeostatic roles of nitric oxide in the normal kidney. Am J Physiol 1997; 272: F561-F578
66. Choi KC, Kim NH, An MR, Kang DG, Kim SW, Lee J. Alterations of intrarenal renin-angiotensin and nitric oxide systems in streptozotocin-induced diabetic rats. Kidney Int Suppl 1997; 60: S23-S27
67. Ishii N, Patel KP, Lane PH, Taylor T, Bian K, Murad F, Pollock JS, Carmines PK. Nitric oxide synthesis and oxidative stress in the renal cortex of rats with diabetes mellitus. J Am Soc Nephrol 2001; 12: 1630-1639
68. Schwartz D, Schwartz IF, Blantz RC. An analysis of renal nitric oxide contribution to hyperfiltration in diabetic rats. J Lab Clin Med 2001; 137: 107-114
69. Sugimoto H, Shikata K, Wada J, Horiuchi S, Makino H. Advanced glycation end-products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-alpha and inducible nitric oxide sinthase in diabetic rat glomeruli. Diabetologia 1999; 42: 878-886
70. Veelken R, Hilgers KF, Hartner A. Nitric oxide synthase isoforms and glomerular hyperfiltration in early diabetic nephropathy. J Am Soc Nephrol 2000; 11: 71-79
71. Trachtman H, Futterweit S, Pine E, Mann J, Valderrama E. Chronic diabetic nephropathy: role of inducible nitric oxide synthase. Pediatric Nephrol 2002; 17: 20-29
72. Noh H, Ha H, Yu MR, Kang SW, Choi KH, Han DS, Lee HY. High glucose increases inducible NO production in cultured rat mesangial cells. Possible role in fibronectin production. Nephron 2002; 90: 78-85
73. Sugimoto H, Shikata K, Matsuda M, Hayashi Y, Hiragushi K, Wada J, Makino H. Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia 1998; 41: 1426-1434
74. Komers R, Allen TJ, Cooper ME. Role of endothelium-derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes. Diabetes 1994; 43: 1190-1197
75. Tilton RG, Ghang K, Hasan KS, Smith SR, Petrash JM, Misko TP, Moore WM, Currie MG, Corbett JA, McDaniel ML, Williamson JR. Prevention of diabetic vascular dysfunction by guanidines: inhibition of nitric oxide synthase vs. advanced glycation end-product formation. Diabetes 1993; 42: 221-232
76. Pieper GM, Dembdy K, Siebeneich W. Long-term treatment in vivo with NOX-101, a scavenger of nitric oxide, prevents diabetes-induced endothelial dysfunction. Diabetologia 1998; 41: 1220-1226
77. Mattar AL, Fujihara CK, Ribeiro MO, de Nucci G, Zatz R. Renal effects of acute and chronic nitric oxide inhibition in experimental diabetes. Nephron 1996; 74: 136-143
78. De Vriese AS, Stoenoiu MS, Elger M, Devuyst O, Vanholder R, Kriz W, Lameire NH. Diabetes-induced microvascular dysfunction in the hydronephrotic kidney: role of nitric oxide. Kidney Int 2001; 60: 202-210
79. Hiragushi K, Sugimoto H, Shikata K, Yamashita T, Miyatake N, Hikata Y, Wada J, Kumagai I, Fukushima M, Makino H. Nitric oxide system is involved in glomerular hyperfiltration in Japanese normo- and microalbuminuric patients with type 2 diabetes. Diabetes Res Clin Pract 2001; 53: 149-159
80. Marietta MA, Yoon PS, Iyengar R, Leaf CD, Wishnok JS. Macrophage oxidation of L-arginine to nitrite and nitrate: nitric oxide is an intermediate. Biochemistry 1988; 27: 8706-8711
81. Rosselli M, Imthurn B, Keller PJ, Jackson EK, Dubey RK. Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17-estradiol and norethisterone acetate. Hypertension 1995; 25 (Part 2): 848-853
82. Chiarelli F, Cipollone F, Romano F, Tumini S, Costantini F, di Ricco L, Pomilio M, Pierdomenico SD, Marini M, Cuccurullo F, Mezzetti A. Increased circulating nitric oxide in young patients with type 1 diabetes and persistent microalbuninuria. Diabetes 2000; 49: 1258-1263
83. Noh H, Ha H, Yu MR, Kang SW, Choi KH, Han DS, Lee HY. High glucose increases inducible NO production in cultured rat mesangial cells. Possible role in fibronectin production. Nephron 2002; 90: 78-85
84. Tilton RG, Chang KC, Lejeune WS, Stephan CC, Brock TA, Williamson JR. Role of nitric oxide in the hyperpermeability and haemodinamic changes induced by intravenous VEGF. Invest Ophthalmol Vis Sci 1999; 40: 689-696
85. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, Casley DJ, Bach LA, Kelly DJ, Gilbert RE. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999; 42: 579-588
86. De Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol. 2001; 12: 993-1000
87. Craven PA, Studer RK, DeRubertis FR. Impaired NO - dependent cyclic GMP generation in glomeruli from diabetic rats: Evidence for protein kinase C-mediated suppression of the cholinergic response. J Clin Invest 1994; 93: 311-320
88. Craven PA, Studer RK, DeRubertis FR. Impaired nitric oxide release by glomeruli from diabetic rats. Metabolism 1995; 44: 695-698
89. Mc Veigh GE, Brennan GM, Johnstone GD, Mc Dermott BJ, Mc Grath LT, Henry WR, Andrews JW, Hayes JR. Impaired endothelium-dependent vasodilation in patients with type 2 diabetes mellitus. Diabetologia 1992; 35: 771-776
90. Tesfamariam B, Cohen RA. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol 1992; 263: H321-H326
91. Schnackenberg CC, Welch WJ, Wilcox CS. TP receptor-mediated vasoconstriction in microperfused afferent arterioles: roles of O2- and NO. Am J Physiol Renal Physiol 2000; 279: F302-F308
92. Ohishi K, Carmines PK. Superoxide dismutase restores the influence of nitric oxide on renal arterioles in diabetes mellitus. J Am Soc Nephrol 1995; 5: 1559-1566
93. Dai F, Diederich A, Skopec J, Diederich D. Diabetes-induced endothelial dysfunction in streptozotocin-treated rats: role of prostaglandin endoperoxides and free radicals. J Am Soc Nephrol 1993; 4: 1327-1336
94. Schoonmaker GC, Fallet RW, Carmines PK. Superoxide anion curbs nitric oxide modulation of afferent arteriolar Ang II responsiveness in diabetes mellitus. Am J Physiol Renal Physiol 2000; 278: F302-F309
95. Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996; 7: 2495-2508
96. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 1992; 90: 278-281
97. Fujihara CK, Denucci G, Zatz R. Chronic nitric oxide synthesis inhibition aggravates glomerular injury in rats with subtotal nephrectomy. J Am Soc Nephrol 1995; 5: 1498-1507
98. MacKay K, Kondaiah P, Danielpour D, Austin HA III, Brown PD. Expression of transforming growth factor β1 and β2 in rat glomeruli. Kidney Int 1990; 38: 1095-1100
99. Studer RK, DeRubertis FR, Craven PA. Nitric oxide suppresses increases in mesangial cell protein kinase C, transforming growth factor β and fibronectin synthesis induced by thromboxane. J Am Soc Nephrol 1996; 7: 999-1005
100. Baylis C, Harvey J, Engels K. Acute nitric oxide blockade amplifies the renal vasoconstrictor actions of angiotensin II. J Am Soc Nephrol 1994; 5: 211-214
101. Kubes P, Granger DN. Nitric oxide modulates vascular permeability. Am J Physiol 1992; 262: H611-H615
102. Witte MB, Kiyama T, Barbul A. Nitric oxide enhances experimental wound healing in diabetes. Br J Surg 2002; 89: 1594-601
103. Clancy RM, Leszczynska P, Piziak J, Abramson SB. Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on NADPH oxidase. J Clin Invest 1992; 90: 1116-1121
104. Hogg N, Kalyanaraman B, Josef J, Struck A, Parthasarathy S. Inhibition of low density lipoprotein oxidation by nitric oxide. Potential role in atherogenesis. FEBS Lett 1993; 34: 170-174
105. Kourembanas S, McQuillan LP, Leung GK, Faller DV. Nitric oxide regulates the expression of vasocontrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest 1993; 92: 99-104
106. Kaikita K, Fogo AB, Ma L, Schoenhard JA, Brown NJ, Vaughan DE. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation 2001; 104: 839-44
107. Neugebauer S, Baba T, Watanabe T. Association of the nitric oxide synthase gene polymorphism with an increased risk for progression to diabetic nephropathy in type 2 diabetes. Diabetes 2000; 49: 500-503
108. Johannesen J, Tarnow L, Parving HH, Nerup J, Pociot F. CCTTT-repeat polymorphism in the human NOS2-promoter confers low risk of diabetic nephropathy in type 1 diabetic patients. Diabetes Care 2000; 19: 560-562
109. Tsukada T, Yokoyama K, Arai T, Takemoto F, Hara S, Yamada A, Kawaguchi Y, Hosoya T, Igarashi J. Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in human. Biochem Biophys Res Commun 1998; 245: 190-193
110. Taniwaki H, Ishimura E, Matsumoto N, Emoto M, Inaba M, Nishizawa Y. Relation between ACE gene and ecNOS gene polimorphisms and resistive index in type 2 diabetic patients with nephropathy. Diabetes Care 2001; 24: 1653-1660
111. Marsden PA, Heng HHQ, Scherer SW, Stewart RJ, Hall AV, Shi XM, Tsui LC, Schappert KT. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem 1993; 268: 17478-17488
112. Graham A, Heath P, Morten JEN, Markham AF. The human aldose reductase gene maps to region 7q35. Hum Genet 1991; 86: 509-514
113. Heesom AE, Hibberd ML, Millward A, Demaine AG. Polymorphism in the 5-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type 1 diabetes. Diabetes 1997; 46: 287-291
114. Bonner TI, Modi WS, Seuanez HN, O'Brien SJ. Chromosomal mapping of five human genes encoding muscarinic acetylcholine receptors. Cytogenet Cell Genet 1991; 58: 1850-1851
115. Merimee TJ. Diabetic retinopathy. A synthesis of perspectives. N Engl J Med 1990; 322: 978-983
116. Frank RN. Diabetic retinopathy. Prog Retin Eye Res 1995; 14: 361-393
117. Becquet F, Courtois Y, Goureau O. Nitric oxide in the eye: multifaceted roles and diverse outcomes. Surv Ophthalmol 1997; 42: 71-82
118. Yoshida A, Pozdnyakov N, Dang L, Orselli SM, Reddy VN, Sitaramayya A. Nitric oxide synthesis in retinal photoreceptor cells. Vis Neurosci 1995; 12: 493-500
119. Chakravarthy U, Stitt AW, McNally J. Nitric oxide synthase activity and expression on retinal capillary endothelial cells and pericytes. Curr Eye Res 1995; 14: 285-294
120. Goureau O, Hicks D, Courtois Y. Nitric oxide decreases in vivo phagocytosis of photoreceptor outer segments by bovine retina pigmented epithelial cells. J Cell Physiol 1994; 159: 259-262
121. Dighiero P, Reux I, Hauw JJ, Fillet AM, Courtois Y, Goureau O. Expression of inducible nitric oxide synthase in cytomegalovirus-infected glial cells of retinas from AIDS patients. Neurosci Lett 1994; 166: 31-34
122. Goureau O, Bellot J, Thillage B, Courtois Y, de Kozak Y. increased nitric oxide production in endotoxin-induced uveitis. J Immunol 1995; 154: 6518-6523
123. EL-Asrar AMA, Desmet S, Meersschaert A, Dralands L, Missotten L, Geboes K. Expression of the inducible isoform of nitric oxide synthase in the retinas of human subjects with diabetes mellitus. Am J Ophthalmol 2001; 132: 551-556
124. Hattenbach Lo, Allers A, Klais C, Koch F, Hecker M. L-Arginine-nitric oxide pathway-related metabolites in the aqueous humor of diabetic patients. Invest Ophthalmol Vis Sci 2000; 41: 213-217
125. Yilmaz G, Esser P, Kociek N, Aydin P, Heimann K. Elevated vitreous nitric oxide levels in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2000; 130: 87-90
126. Shibuki H, Katai N, Yodoi J, Uchida K, Yoshimura N. Lipid peroxidation and peroxynitrite in retinal ischemia-reperfusion injury. Invest Ophthalmol Vis Sci 2000; 19: 3607-3614
127. Sugimoto H, Shikata K, Matsuda M, Kushiro M, Hayashi Y, Hiragushi K, Wada J, Makino H. Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia 1998; 19: 1426-1434
128. Hartnett ME, Stratton RD, Browne RW, Rosner BA, Lanham RJ, Armstrong D. Serum markers of oxidative stress and severity of diabetic retinopathy. Diabetes Care 2000; 19: 234-240
129. Goureau O, Hicks D, Courtois Y. Human retina pigment epithelial cells produce nitric oxide in response to cytokines. Biochem Biophys Res Comm 1994; 198: 120-126
130. Ziche M, Morbidelli L, Masini E, Amerini S, Granger HJ, Maggi CA, Geppetti P, Ledda F. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 1994; 94: 2036-2044
131. Aiello LP, Wong JS. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int 2000; 19: S113-119
132. Tilton RG, Chang KC, Lejeune WS, Stephan CC, Brock TA, Williamson JR. Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF. Invest Ophthalmol Vis Sci 1999; 19: 689-696
133. Papapetropoulos A, Garcia-Cardenya G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997; 19: 3131-3139
134. Fukumura D, Gohongi T, Kadambi A, Izumi Y, Ang J, Yun CO, Buerk DG, Huang PL, Jain RK. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci USA 2001; 19: 2604-2609
135. Brooks SE, Gu X, Samuel S, Marcus DM, Bartoli M, Huang PL, Caldwell RB. Reduced severity of oxygen-induced retinopathy in eNOS-deficient mice. Invest Ophthalmol Vis Sci 2001; 19: 222-228
136. Sennlaub F, Courtois Y, Goureau O. Inducible nitric oxide synthase mediates the change from retinal to vitreal neovascularization in ischemic retinopathy. J Clin Invest 2001; 19: 717-725
137. Hernandez C, Lecube A, Segura RM, Sararols L, Simo R. Nitric oxide and vascular endothelial growth factor concentrations are increased but not related in vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med 2002; 19: 655-60
138. Bek T. Transretinal histopathological changes in capillary-free areas of diabetic retinopathy. Acta Ophthalmol 1994; 72: 409-415
139. Palmowski AM, Sutter EE, Bearse Jr MA, Fung W. Mapping of retinal function in diabetic retinopathy using the multifocal electroretinogram. Invest Opthalmol Vis Sci 1997; 38: 2586-2596
140. Brune B, von Knethen A, Sandau KB. Nitric oxide and its role in apoptosis. Eur J Pharmacol 1998; 351: 261-272
141. Yamakura F, Taka H, Fujimura T, Murayama K. Inactivation of human manganese-superoxide dismutase by peroxynitrate is caused by exclusive nitration of tyrosine 34 to 3-nitrotyrosine. J Biol Chem 1998; 273: 14085-14089
142. Mac Millan-Crow LA, Thompson A. Tyrosine modifications and inactivation of active site manganese superoxide dismutase mutant (Y34F) by peroxynitrite. Arch Biochem Biophys 1999; 366: 82-88
143. Aulak KS, Miyagi M, Yan L, West KA, Massillon D, Crabb JW, Stuehr DJ. Proteomic method identifies proteins nitrated in vivo during inflammatory challenge. Proc Natl Acad Sci USA 2001; 98: 12 056-12 061
144. Bolanos JP, Almeida A, Fernandez E, Medina JM, Land JM, Clark JB, Heales SJ. Potental mechanisms for nitric oxide-mediated impairment of brain mitochondrial energy metabolism. Biochem Soc Trans 1997; 25: 944-949
145. Dawson VL, Brahmbhatt HP, Mong JA, Dawson TM. Expression of inducible nitric oxide synthase causes delayed neurotoxicity in primary mixed neuronal-glial cortical cultures. Neuropharmacology 1994; 33: 1425-1430
146. Dawson VL, Dawson TM. Nitric oxide neurotoxicity. J Chem Neuroanat 1996; 10: 179-190
147. Nogawa S, Forster C, Zhang F, Magayama M, Ross ME, Iadecola C. Interaction between inducible nitric oxide sinthase and cycloxygenase-2 after cerebral ischemia. Proc Natl Acad Sci USA 1998; 95: 10966-10971
148. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984; 19: 520-526
149. Warpeha KM, Xu W, Liu L, Charles IG, Patterson CC, Ah-Fat F, Harding S, Hart PM, Chakravarthy U, Hughes AE. Genotyping and functional analysis of a polymorphism (CCTTT)(n) repeat of NOS2A in diabetic retinopathy. FASEB J 1999; 19: 1825-1832
150. Taverna MJ, Sola A, Guyot-Argenton C, Pacher N, Bruzzo F, Chevalier A, Slama G, Reach G, Selam JL. eNOS4 polymorphism of the endothelial nitric oxide synthase predicts risk for severe diabetic retinopathy. Diabet Med 2002; 19: 240-5
151. Tsukada T, Yokoyama K, Arai T, Takemoto F, Hara S, Yamada A, Kawaguchi Y, Hosoya T, Igari J. Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. Biochem Biophys Res Commun 1998; 19: 190-193
152. Kumaramanickavel G, Sripriya S, Vellanki RN, Upadyay NK, Badrinath SS, Rajendran V, Sukumar B, Ramprasad VL, Sharma T. Inducible nitric oxide synthase gene and diabetic retinopathy in Asian Indian patients. Clin Genet 2002; 61: 344-348
153. Ando A, Yang A, Nambu H, Campochiaro PA. Blockade of nitric-oxide synthase reduces choroidal neovascularization. Mol Pharmacol 2002; 62: 539-544
154. Hangai M, Miyamoto K, Hiroi K, Tujikawa A, Ogura Y, Honda Y, Yoshimura N. Roles of constitutive nitric oxide synthase in postischemic rat retina. Invest Ophthalmol Vis Sci 1999; 40: 450-458
155. Parmentier-Batteur S, Bohme GA, Lerouet D, Zhou-Ding L, Beray D, Margaill I et al. Antisense oligodeoxynucleotide to inducible nitric oxide synthase protects against transient focal cerebral ischemia-induced brain injury. J Cereb Blood Flow Metab 2001; 19:15-21
156. Hammes HP, Martin S, Federlin K, Geusen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 1991; 88: 11555-11558
157. Tilton RG, Chang K, Hasan KS, Chang K, Hasan KS, Smith SR, Petrash JM, Misko TP, Moore WM, Currie MG, Corbett JA, McDaniel ML. Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation Diabetes 1993; 42: 221-232
158. Morrish NJ, Stevens LK, Fuller JH, Jarrett RJ, Keen H. Risk factors for macrovascular disease in diabetes mellitus: the London follow-up to the WHO Multinational Study of Vascular Disease in Diabetics. Diabetologia 1991; 34: 590-594
159. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000; 101: 1899-1906
160. Rosen P, Du X, Sui GZ. Molecular mechanisms of endothelial dysfunction in the diabetic heart. Adv Exp Med Biol 2001; 498: 75-86
161. Federici M, Menghini R, Mauriello A, Hribal ML, Ferrelli F, Lauro D, Sbraccia P, Spagnoli LG, Sesti G, Lauro R. Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosilation modification of signaling proteins in human coronary endothelial cells. Circulation 2002; 106: 466-472
162. Adam JM, Ettelaie C, Naseem KM, James NJ, Bradley NJ, Bruckdorfer KR. Modification of tissue factor by peroxynitrite influences its procoagulant activity. FEBS Lett 1998; 16; 429: 347-50
163. Napoli C, Lerman LO, de Nigris F, Loscalzo J, Ignarro LJ. Glycoxidized low-density lipoprotein downregulates endothelial nitric oxide synthase in human coronary cells. J Am Coll Cardiol 2002; 40: 1515-22
164. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman MC. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995; 377: 239-242
165. Moroi M, Zhang L, Yasuda T, Virmani R, Gold HK, Fishman MC, Huang PL. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin Invest 1998; 101: 1225-1232
166. Sampaio RC, Tanus-Santos JE, Melo SE, Hyslop S, Franchini KG, Luca IA, Moreno H Jr. Hypertension plus diabetes mimics the cardiomyopathy induced by nitric oxide inhibition in rats. Chest 2002; 122: 1412-1420
167. Egashira K, Katsuda Y, Mohri M, Kuga T, Tagawa T, Shimokawa H, Takeshita A. Basal release of endothelium-derived nitric oxide at site of spasm in patients with variant angina. J Am Coll Cardiol 1996; 27: 1444-1449
168. Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, Panza JA, Cannon RO 3rd. Nitric oxide activity in the human coronary circulation: Impact of risk factors for coronary atherosclerosis. J Clin Invest 1995; 95: 1747-1755
169. Kobayashi T, Kamata K. Effect of chronic insulin treatment on NO production and endothelium-dependent relaxation in aortae from established STZ-induced diabetic rats. Atherosclerosis 2001; 155: 313-320
170. Huszka M, Kaplar M, Rejto L, Tornai I, Palatka K, Laszlo P, Udvardy M. The association of reduced endothelium derived relaxing factor-NO production with endothelial damage and increased in vivo platelet activation in patients with diabetes mellitus. Thromb Res 1997; 86: 173-80
171. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332:481-487
172. Masumoto A, Hirooka Y, Hironaga K, Eshima K, Setoguchi S, Egashira K, Takeshita A. Effect of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin). Am J Cardiol 2001; 88: 1291-1294
173. Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui-Hirai H, Thakur NK, Egashira K, Iguchi A. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001; 104: 376-379
174. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365-372
175. Trovati M, Anfossi G, Massucco P, Mattiello L, Costamagna C, Piretto V, Mularoni E, Cavalot F, Bosia A, Ghigo D. Insulin stimulates nitric oxide synthesis in human platelets and, through nitric oxide, increases platelet concentrations of both guanosine-3′,5′-cyclic monophosphate and adenosine-3′-5′-cyclic monophosphate. Diabetes 1997; 46:742-749
176. Cooke JP, Dzau VJ. Nitric oxide synthase: Role in the genesis of vascular disease. Annu Rev Med 1997; 48: 489-509
177. Liao JK. Endothelium and acute coronary syndromes. Clin Chem 1998; 44: 1799-1808
178. Dandona P, Aljada A, Mohanty P. The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia 2002; 45: 924-930
179. Aljada A, Saadeh R, Assian E, Ghanim H, Dandona P. Insulin inhibits the expression of intercellular adhesion molecule-1 by human aortic endothelial cells through stimulation of nitric oxide. J Clin Endocrinol Metab 2000; 85: 2572-2575
180. Aljada A, Ghanim H, Saadeh R, Dandona P. Insulin inhibits NF-kB and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab 2001; 86: 450-453
181. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad S. Insulin inhibits intranuclear nuclear factor kB and stimulates IkB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 2001; 86: 3257-3265
182. Ghanim H, Garg R, Aljada A, Mohanty P, Kumbkarni Y, Assian E, Hamouda W, Dandona P. Suppression of nuclear factor-kB and stimulation of inhibitor kB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 2001; 86: 1306-1312
183. Aljada A, Ghanim H, Assian E, Dandona P. Tumor necrosis factor-alpha inhibits insulin-induced increase in endothelial nitric oxide sinthase and reduces insulin receptor content and phosphorylation in human aortic endothelial cells. Metabolism 2002; 51: 487-491
184. Numaguchi K, Egashira K, Takemoto M, Kadokami T, Shimokawa H, Sueishi K, Takeshita A. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension 1995; 26: 957-962
185. Takemoto M, Egashira K, Usui M, Numaguchi K, Tomita H, Tsutsui H, Shimokawa H, Sueishi K, Takeshita A. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 1997; 99: 278-287
186. Takemoto M, Egashira K, Tomita H, Usui M, Okamoto H, Kitabatake A, Shimokawa H, Sueishi K, Takeshita A. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: Effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension 1997; 30: 1621-1627
187. Tomita H, Egashira K, Kubo-Inoue M, Usui M, Koyanagi M, Shimokawa H, Takeya M, Yoshimura T, Takeshita A. Inhibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels. Arterioscler Thromb Vasc Biol 1998; 18: 1456-1464
188. Tomita H, Egashira K, Ohara Y, Takemoto M, Koyanagi M, Katoh M, Yamamoto H, Tamaki K, Shimokawa H, Takeshita A. Early induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 1998; 32: 273-279
189. Kubo-Inoue M, Egashira K, Usui M, Takemoto M, Ohtani K, Katoh M, Shimokawa H, Takeshita A. Long-term inhibition of nitric oxide synthesis increases arterial thrombogenecity through angiotensin II-induced expression of tissue factor and resultant production of thrombin in rats. Am J Physiol Heart Circ Physiol 2002; 282: H1478-H1484
190. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodelling and atherogenesis: the good, the bad, the ugly. Circ Res 2002; 90: 251-262
191. Usui M, Egashira K, Kitamoto S, Koyanagi M, Katoh M, Kataoka C, Shimokawa H, Takeshita A. Pathogenic role of oxidative stress in vascular angiotensin-converting enzyme activation in long-term blockade of nitric oxide synthesis in rats. Hypertension 1999; 34: 546-551
192. Kitamoto S, Egashira K, Kataoka C, Usui M, Koyanagi M, Takemoto M, Takeshita A. Chronic inhibition of nitric oxide synthesis in rats increases aortic superoxide anion production via the action of angiotensin II. J Hypertens 2000; 18: 1795-1800
193. Koyanagi M, Egashira K, Kitamoto S, Ni W, Shimokawa H, Takeya M, Yoshimura T. Role of monocyte chemoattractant protein-1 in cardiovascular remodelling induced by chronic blockade of nitric oxide synthesis. Circulation 2000; 102: 2243-2248
194. Koyanagi M, Egashira K, Kubo-Inoue M, Usui M, Kitamoto S, Tomita H, Shimokawa H, Takeshita A. Role of transforming growth factor-beta 1 in cardiovascular inflammatory changes induced by chronic inhibition of nitric oxide synthesis. Hypertension 2000; 35: 86-90